UK drugmakers body ABPI wants changes at NHS watchdog NICE to fit 'value-based' era
Changes are needed in the remit of the UK drugs watchdog, the National Institute for Health and Clinical Excellence (NICE), to equip it for the future “value-based” era envisaged by government, according to the trade group the Association of the British Pharmaceutical Industry (ABPI).
Speaking yesterday at the Westminster Health Forum in London, which is holding a seminar on the changing role of the NICE, Richard Barker, director general of the ABPI, set out a three-point plan for the future:
• Broaden NICE’s definition of value to capture all the key elements of health care innovation, and reflect uncertainties in early assessment of medicines in value ranges.
• Refocus attention on clinical best practice and quality standards and how innovation can advance both.
• Dismantle National Health Service (NHS) processes that “second-guess” NICE conclusions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze